Clinical Trials Market Research Report- Forecast till 2030

Clinical Trials Market Research Report: by Phase (Phase I, Phase II, Phase III) by Study Design (Interventional, Observational and Expanded Access), Indication (Autoimmune/Inflammation) by End User (Medical Institutes, Hospitals)-Forecast Till 2030

ID: MRFR/HC/6317-HCR | February 2023 | Region: Global | 110 Pages         

Clinical Trials Market Speak to Analyst Request a Free Sample

Clinical trials market

The global clinical trials market Size is expected to expand USD 47,500 Million at a CAGR of 5.70% from 2022 to 2030.

By Phase Phase I Phase II Phase III
By Study Design Interventional Observational and Expanded Access
By Indication Autoimmune/Inflammation
By End User Medical Institutes Hospitals
Key Players
Companies Profiled   Charles River Laboratories   Paraxel International Corporation   Quintiles IMS   ICON plc   SGS SA   Eli Lilly and Company   Novo Nordisk A/S   Clinipace   Laboratory Corporation of America   Pfizer
Market Driving Forces   Development of new treatments methods such as personalized medicine   Growing evolution in technology
Request a Free Sample

Clinical Trials Market Overview

Clinical Trials Market is expected to reach USD 47,500 Million by 2030 at 5.70% CAGR during the forecast period 2022-2030. The market is growing mainly due to globalization and the surge in the development of new products. The treatment modalities like personalized medicines, innovative technologies, and the increasing need for a contract research organization to conduct clinical trials will expand the market. The growing number of chronic diseases, growing demand for biologists, the demand for personalized medicines increasing investment in research and development in the pharmaceutical sector will contribute to the uprise of the market. Due to the pandemic, the spike in the number of trials globally has contributed to enhancing the market size. Research studies are basically when it is studied and performed over people to evaluate a medical, behavioral, or surgical intervention called clinical trials. It is carried to detect a disease in its beginning stage and treat it before it begins to affect the body more severely. Several people are dying due to the error in detecting the disease, so this technology helps recognize the condition. North America is expected to hold the largest market size as the place adopts new technologies.

Clinical Trials Market Segmentation

The clinical trials industry is segmented on the basis of phase, study design, indication and end users. On the basis of the phase, the clinical trials market is categorized into phase I, phase II, phase III, and phase IV. On the basis of study design, the clinical trials market is segmented into interventional, observational and expanded access. On the basis of indication, the clinical trials market is segmented into autoimmune/inflammation, pain management, oncology, central nervous system (CNS) condition, diabetes, obesity, cardiovascular and others. On the basis of the end-user, the clinical trials market is segmented into dental hospitals & clinics, dental institutes and dental academic and research institutes.

Clinical Trials Market Regional Analysis

The Americas dominate the clinical trials market owing to presence of large number of pharmaceutical companies, huge patient population and growing innovation to develop new products. Also, the increasing cases of patients suffering from cancer, diabetes and other life-threatening diseases promotes the clinical trial methods to develop treatment options. According to the American Cancer Society in 2018, 63,340 new cases of kidney cancer are estimated in the U.S which increases the demand for innovative drugs. The National Cancer Institute is involved in clinical trials on different types of cancer to develop treatment methods on it. The clinical trials market in Europe is the second largest market. Factors such as high R&D spending of the pharmaceutical industry and increasing prevalence of disease and new disease cases is predictable to give further boost to the clinical trials market. In Europe has introduced new regulations in clinical trials in which the European Commission has wished to give a strong motivation to scientific research and industrial progress.

The introduction of new favourable regulations for clinical trials and increasing demand for new products across the Europe would boost the clinical trials market growth. Asia Pacific region is the fastest growing market owing to the increasing prevalence of diseases, growing focus on developing medication for rare diseases and growing government support with regards to development of the outsourcing hubs enhances the clinical trials market. In countries like India, China and Australia the developing economy and low cost to operate clinical trial facilities supplies the clinical trials market growth in this region. On the other hand, the Middle East & Africa has the least share in the clinical trials market. This can be attributed to the presence of poor economies, less technical facilities, lack of scientific knowledge and a smaller number of clinical trials centers especially in the African region decreases the clinical trials market growth. It is estimated that a majority of the clinical trials market in the Middle East & Africa region is held by the Middle East due to the presence of a well-developed healthcare sector and huge healthcare expenditure the economies like Saudi Arabia, Kuwait, and Qatar within the region.  

Key Players 

some of the major players for clinical trials market are 

  • Charles River Laboratories

  • Paraxel International Corporation

  • Quintiles IMS

  • ICON plc

  • SGS SA

  • Eli Lilly and Company

  • Novo Nordisk A/S

  • Clinipace

  • Laboratory Corporation of America

  • Pfizer

Recent DevelopmentIn May 2022

Saol Therapeutics has dosed the first subject in Phase II RAISE Spasticity trial of SL-1002 to treat adults with limb spasticity. The company anticipates topline findings from the practice next year.

High-level results from the DELIVER Phase III trial showed AstraZeneca’s Farxiga (dapagliflozin) reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or worsening heart failure (HF).

Tetra Bio-Pharma Inc, a leader in cannabinoid-derived drug discovery and development, has announced that it has entered into a research and development agreement with Cannvalate Pty Ltd for the initiation of the REBORN®, PLENITUDE®, and CAUMZ® and clinical trials in Australia.

Intended Audience

  • Pharmaceutical Companies

  • Biotechnological Institutes

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research And Consulting Service Providers

Report Scope:

Report Attribute/Metric Details
  Market Size   USD 47,500 Million
  CAGR   5.70%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Phase, Study design, Indication and End users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Charles River Laboratories,Paraxel International Corporation, Quintiles IMS, ICON plc, SGS SA, Eli Lilly and Company, Novo Nordisk A/S, Clinipace, Laboratory Corporation of America, Pfizer and Others
  Key Market Opportunities   New product development
  Key Market Drivers

  • Development of new treatments methods such as personalized medicine
  • Growing evolution in technology
  • Rising demand for contract research organization (cros) to conduct clinical trials.

  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Clinical trials market is expected to exhibit a solid 5.70% CAGR over the forecast period.

    The growing demand to find effective cures to chronic and infectious diseases is the major driver for the clinical trials market.

    By indication, the global clinical trials market is segmented into autoimmune disorders, pain management, oncology, CNS conditions, diabetes, obesity, CVDs, and others.

    The Americas dominate the global clinical trials market, followed by Europe.

    Leading players in the global clinical trials market include Eli Lilly, Novo Nordisk, Quintiles IMS, Charles River Laboratories, and others.